TORTOLA, British Virgin Islands–(BUSINESS WIRE)–Juvenescence
Limited (“Juvenescence”), a company focused on the development of
therapeutics for ageing and the diseases of ageing, announced the
appointment of Karim Hakimzadeh to its Board of Directors. The
appointment increases the size of the Board of Directors to five members.
“It’s a great privilege to serve on the board of a company in one of
the most exciting fields in modern medicine,” said Karim. “Having
followed the longevity space for a number of years, Juvenescence
represents the most compelling opportunity I’ve seen yet to translate a
hugely ambitious scientific undertaking into potentially life-extending
“Karim will be a strong addition to Juvenescence as we continue to
build a diverse team of professionals with expertise in biotech, drug
development, and finance” said Dr. Greg Bailey, the Chief Executive
Officer of Juvenescence. “I have had the pleasure of looking at a
number of projects with Karim, including Medivation and Biohaven
Pharmaceuticals, and I have been highly impressed by his foresight,
diligence, and investment acumen. Juvenescence will benefit from his
oversight and direction.”
Background on Karim Hakimzadeh
Karim is an investor with a decade of experience backing transformative
companies in technology and the life sciences. Since 2012, he has run a
New York-based public market fund that has outperformed the S&P since
inception. Recently, he has shifted focus to earlier stage ventures and
intends to devote much of his investment activity going forward to the
longevity space. Karim attended St Paul’s School in London. He has a
degree in economics from Harvard University.
Juvenescence Limited is a biotech company focused on therapies to
increase healthy human longevity. It was founded in 2017 by Jim Mellon,
Dr. Greg Bailey, Dr. Declan Doogan, Anthony Chow, and Alexander Pickett.
The Juvenescence team are highly experienced drug developers, and serial
entrepreneurs with a track record of success in life sciences and drug
development. Juvenescence is focussed on developing therapeutics that
alter ageing or age-related diseases.
Juvenescence believes that recent advances in science have greatly
improved our understanding of the biology of ageing and creates the
opportunity to develop therapeutics now that can slow, halt or
potentially reverse elements of ageing.
Chief Operating Officer
617 652 0124